3M Drug Delivery Systems has entered a new phase in an ongoing collaboration with Panacea Pharmaceuticals, a Gaithersburg, Maryland-headquartered pharmaceutical company focused on therapies for cancer and neurodegenerative diseases, in which the two companies will develop a dermal-delivery method for Panacea’s investigational cancer vaccine.

The companies will develop the delivery method using 3M’s hollow microstructured transdermal system (hMTS). The hMTS consists of a transdermal patch paired with a high-volume reproducible delivery capability to the dermis via the use of hollow microneedles. For Panacea’s purposes, the company must deliver a 1-milliliter volume of its cancer vaccine to the dermis.

Source: 3M Drug Delivery Systems